

1 **SUPPLEMENTARY INFORMATION**

2 **Title:**

3 Targeting the transmembrane cytokine co-receptor neuropilin-1 in distal tubules improves
4 renal injury and fibrosis

5 **Author list:**

6 Yinzheng Li¹, Zheng Wang¹, Huzi Xu¹, Yu Hong¹, Mengxia Shi¹, Bin Hu¹, Xiuru Wang¹,
7 Shulin Ma¹, Meng Wang¹, Chujin Cao¹, Han Zhu¹, Danni Hu¹, Chang xu¹, Yanping Lin¹,
8 Gang Xu^{1,*}, Ying Yao^{1,2,*}, Rui Zeng^{1,3,*}

9 **Affiliations:**

10 ¹ Division of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of
11 Science and Technology, 1095 Jiefang Ave, Wuhan 430030, China

12 ² Department of Nutrition, Tongji Hospital, Tongji Medical College, Huazhong University of
13 Science and Technology, 1095 Jiefang Ave, Wuhan 430030, China

14 ³ Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of
15 Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of
16 Medical Sciences, Wuhan 430030, China.

17 *Correspondence: zengrui@tjh.tjmu.edu.cn (R.Z.), yaoyingkk@126.com (Y.Y.),
18 xugang@tjh.tjmu.edu.cn (G.X.)

19


20 **Inventory of Supporting Information:**

21 Supplementary Figures 1 to 10

22 Supplementary Tables 1 to 3

23 References 1 to 3

24



25

26 **Supplementary Figure 1. A single-cell transcriptomics landscape of mouse kidney**

27 **after I-R.** (A) A schematic diagram illustrating the workflow for single-cell RNA sequencing

28 sample submission. Supplementary Figure 1A, created with BioRender.com, released

29 under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.


30 (B) A UMAP presentation depicted cells profiled from individual mouse kidneys under

31 healthy or IR conditions. The surrounding circular layouts represent the cell number of each

32 population on a logarithmic scale. PT, proximal tubule; PT-Injured, injured PT; LOH, loop

33 of Henle ; DCT, distal convoluted tubule; CD-PC, principal cell of collecting duct; CD-IC,

34 intercalated cell of collecting duct; EC, endothelial cell; Peri, Pericytes; Fib, fibroblast; Myo,
35 myofibroblast; Prolife cell, proliferating cell; Macro, macrophage; T lymph, T lymphocyte; B
36 lymph, B lymphocyte; cDC, conventional dendritic cell; pDC, plasmacytoid dendritic cell;
37 Neutrophil, Neutrophil. (C) Dotplot showing gene expression levels and proportions of
38 cluster-specific marker genes in each cluster. (D) Expression levels of *Tgfr2* and *Tgfr3*
39 in kidney after IR surgery.
40




41

42 **Supplementary Figure 2. *Nrp1* is expressed in distal TECs.** (A) Expression levels of

43 *Nrp1* in mice with nephrotic syndrome. Figure created with

44 <https://singlecell.broadinstitute.org/>. The data is pubic in Single Cell Portal whitepaper

45 (<https://www.biorxiv.org/content/10.1101/2023.07.13.548886v1>). (B) Expression of *Nrp1* in
46 COVID-19 autopsy donors. Image from <https://singlecell.broadinstitute.org/>. The data is
47 public in Single Cell Portal whitepaper
48 (<https://www.biorxiv.org/content/10.1101/2023.07.13.548886v1>). (C) The expression levels
49 of *Nrp1* in the mice kidneys after UUO, sodium oxalate (SO), IR, cisplatin (CP), and folic
50 acid (FA). The data comes from GSE197266. (D) Expression of *Nrp1* and *Cdh16* in mouse
51 renal space transcriptomics. Image from <https://www.spatialomics.org/SpatialDB/>. (E) *Nrp1*
52 immunofluorescence staining with antibody from Santa cruz, R&D and Abcam. (F) Co-
53 expression of *Nrp1* with *Kim1* with immunofluorescence staining. (G) Expression levels of
54 *Nrp2* in kidney after IR surgery in our study. (H) Co-expression of *Nrp1* and TGF- β
55 receptors in DT cells.
56




57

58 **Supplementary Figure 3. Knockout or overexpression of *Nrp1* in distal TECs.** (A) A

59 schematic diagram illustrating tubular *Nrp1* deletion. (B) Mouse tail DNA analysis to

60 validate gene knockouts. (C) *Nrp1* immunofluorescence staining after IR in mice. (D)

61 Histological analyses of tissues from the heart, liver, spleen, lungs, and kidneys of the gene
62 knockout mice by H&E and PAS staining. Scale bar, 50 μ m. (E) Validation of Nrp1
63 expression in gene knockout by Western Blotting ($n = 6$ per group). (F) A schematic
64 diagram illustrating the subcapsular injection of lentivirus for Nrp1 overexpression. (G)
65 Fluorescence images of Nrp1 lentivirus with GFP. Scale bar, 20 μ m. (H) Fluorescence
66 images of Nrp1 on day 5 after I-R in mice. Scale bar, 20 μ m. (I) Ratio of kidney weight
67 versus body weight of mice (For Vehi, $n=5$; Nrp1, $n=4$; Vehi+IR, $n=6$; Nrp1+IR, $n=5$).
68 Plasma BUN concentrations and creatinine (CR) concentrations in groups (For Vehi, $n=5$;
69 Nrp1, $n=4$; Vehi+IR, $n=6$; Nrp1+IR, $n=5$). (J) Levels of mRNA encoding *Nrp1* by RT-qPCR
70 (For Vehi, $n=5$; Nrp1, $n=4$; Vehi+IR, $n=6$; Nrp1+IR, $n=5$). (K) Representative micrographs
71 and corresponding statistical scores of periodic acid-Schiff (PAS) staining and Kim1
72 immunofluorescence staining on day 5 after IR in mice (For Vehi, $n=5$; Nrp1, $n=4$; Vehi+IR,
73 $n=6$; Nrp1+IR, $n=5$). (L) Representative micrographs and corresponding statistical scores
74 of periodic acid-Schiff (PAS) staining on day 1 after IR in mice ($n = 4$ per group). (M) Plasma
75 BUN concentrations and creatinine (CR) concentrations in groups on day 1 after IR in mice
76 ($n = 4$ per group). Scale bar, 20 μ m. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$ as determined by
77 one-way ANOVA. Data represent mean \pm SEM. Source data are provided as a Source
78 Data file.
79



80

81 **Supplementary Figure 4. Knockout of *Nrp1* in distal TECs alleviates renal fibrosis**


82 **caused by UUO and 5/6 nephrectomy. (A) Whole-slide image of mouse kidney paraffin**

83 **sections stained with PAS after UUO surgery and statistical analysis of renal tubular injury**

84 **scores ($n = 5$ per group). (B) Representative micrographs and corresponding statistical**

85 **scores of Sirius red and Masson on day 7 after UUO in mice ($n = 5$ per group). (C)**

86 Expression levels of kidney damage related indicators (*Havcr1* and *Lcn2*) and fibrosis
87 related indicators (*Acta2*, *Pdgfrb*, *Col1a1* and *Fn1*) at day 7 after UUO determined using
88 RT-qPCR ($n = 5$ per group). (D) Representative micrographs and corresponding statistical
89 scores of PAS, Sirius red and Masson on day 14 after 5/6 nephrectomy in mice ($n = 5$ per
90 group). (E) Expression levels of kidney damage related indicators (*Havcr1* and *Lcn2*) and
91 fibrosis related indicators (*Acta2*, *Pdgfrb*, *Col1a1* and *Fn1*) at day 14 after 5/6 nephrectomy
92 determined using RT-qPCR (For Sham, $n=5$; Vehi+5/6Nx14, $n=4$; Tmx+5/6Nx14, $n=5$).
93 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ as determined by one-way ANOVA. Scale bar, 20 μm .
94 Data represent mean \pm SEM. Source data are provided as a Source Data file.
95



96

97 **Supplementary Figure 5. Changes in enzyme regulating lysine modifications and**98 **other classical post-translational modifications after I-R-induced injury. (A)**


99 Expression levels of decrotonylases and crotonyltransferases genes in kidney after I-R

100 surgery. (B) Western blotting analysis showing the changes in different lysine modifications

101 after I-R and *Nrp1* knockout. (C) Expression levels of *Acox3* in kidney after I-R surgery.

102 Source data are provided as a Source Data file.

103



104

105 **Supplementary Figure 6. *Nrp1* inhibits OXPHOS levels in distal TECs.** (A) Regulated

106 KEGG pathways in I-R groups compared to sham groups in scRNA-seq data. The

107 horizontal axis represents the number of genes with significant differences enriched in


108 different pathways, positive values represent the number of genes upregulated by I-R

109 compared to the sham group, and negative values represent the number of genes

110 downregulated by I-R compared to the sham group. (B) Gene Set Enrichment Analysis

111 (GSEA) plot depicting the enrichment of gene sets related to OXPHOS, TCA, and
112 glycolysis/gluconeogenesis pathways in *Nrp1*+ DT cells compared to *Nrp1*- DT cells. (C)
113 The OXPHOS-related heatmap in IRD5 kidney bulk RNA-seq and pTECs proteomics (*n* =
114 4 per group). (D) After IRD5, *Nrp1*+DT compared with *Nrp1*-DT, the pathway map of gene
115 transcription level changes in OXPHOS, TCA and glycolysis pathway in scRNA-seq data.
116 Scale: Blue corresponds to gene downregulation in *Nrp1*+DT compared to *Nrp1*- DT, while
117 gray indicates no statistically significant change in gene expression. Source data are
118 provided as a Source Data file.

119



120


121 **Supplementary Figure 7. Nrp1 inhibited OXPHOS levels.** Renal tissue expression of

122 OXPHOS and TCA at day 5 after IR determined using RT-qPCR (For Sham, $n=9$; Vehi+IR,

123 $n=7$; Tmx+IR, $n=7$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ as determined by one-way ANOVA.

124 Data represent mean \pm SEM. Source data are provided as a Source Data file.

125



126

127

Supplementary Figure 8. *Nrp1*+DT cells are rich in expression of cell death-related

128

genes and secrete large amounts of pro-fibrotic factors. (A) Dotplot of *Col4a1*, *Pdgfb*,

129

and *Pdgfa* expression in DT cells expressing the apoptosis representative gene *Casp8*. (B)

130

Dotplot of *Col4a1*, *Pdgfb*, and *Pdgfa* expression in DT cells expressing the autophagy

131

representative gene *Atg101*. (C) Dotplot of *Col4a1*, *Pdgfb*, and *Pdgfa* expression in DT

132

cells expressing the pyroptosis representative gene *Casp4*. (D) Dotplot of *Col4a1*, *Pdgfb*,

133

and *Pdgfa* expression in DT cells expressing the ferroptosis representative gene *Acs14*. (E)


134

Dotplot of *Col4a1*, *Pdgfb*, and *Pdgfa* expression in DT cells expressing the necroptosis

135

representative gene *Mkl1*.

136



137

138 **Supplementary Figure 9. Construction of distal tubular-specific *Nrp1* and *Tgfr1***

139 **double-gene knockout mice, as well as myofibroblast-specific *Nrp1* knockout mice**


140 **and pericyte-specific *Nrp1* knockout mice. (A) A schematic diagram illustrating the**

141 **tubular-specific *Tgfr1* knockout. (B) A schematic diagram illustrating the tubular-specific**

142 ***Nrp1* and *Tgfr1* double-gene knockout. (C) A schematic diagram illustrating the**

143 **myofibroblast-specific *Nrp1* knockout. (D) A schematic diagram illustrating the pericyte-**

144 specific *Nrp1* knockout. (E) RT-qPCR experiments were conducted using mice from A to
145 determine the expression levels of *Nrp1* and/or *Tgfbr1* (For Sham, $n=6$; Vehi+IRD14, $n=5$;
146 Tmx+IRD14, $n=7$). (F) RT-qPCR experiments were conducted using mice from B to
147 determine the expression levels of *Nrp1* and/or *Tgfbr1* ($n = 6$ per group). (G) RT-qPCR
148 experiments were conducted using mice from C to determine the expression levels of *Nrp1*
149 and/or *Tgfbr1* (For Sham, $n=7$; Vehi+IRD14, $n=7$; Tmx+IRD14, $n=6$). (H) RT-qPCR
150 experiments were conducted using mice from D to determine the expression levels of *Nrp1*
151 and/or *Tgfbr1* ($n = 5$ per group). (I) Histological analyses of section from the heart, liver,
152 spleen, lungs, and kidneys of the gene knockdown mice by H&E and PAS staining. $*P <$
153 0.05 , $**P < 0.01$, $***P < 0.001$ as determined by one-way ANOVA. Scale bar, $50 \mu\text{m}$. Data
154 represent mean \pm SEM. Source data are provided as a Source Data file.
155



156

157 **Supplementary Figure 10. Injection of *Nrp1* and *Tgfr1* siRNA under the renal capsule,**

158 **or deletion of *Nrp1* in myfibroblasts or pericytes attenuates I-R-induced renal injury.**

159 (A) Representative micrographs and corresponding statistical scores of PAS and Kim1

160 immunofluorescence staining on day 5 after renal capsule injection of *Nrp1* and *Tgfr1*
161 siRNA in C57 mice with I-R injury. Ratio of kidney weight versus body weight of mice.
162 Plasma BUN concentrations and CR concentrations in sham, Vehi + IR, *Nrp1* siRNA + IR,
163 or *Nrp1* siRNA + *Tgfr1* siRNA + IR groups at 5 days. For Sham, $n=7$; Vehi+IRD5, $n=6$; *Nrp1*
164 siRNA+IRD5, $n=5$; *Nrp1* siRNA+*Tgfr1* siRNA+IRD5, $n=5$. (B) Expression levels of *Nrp1*
165 and *Tgfr1* in kidneys of C57 mice with IR injury, after renal capsule injection of *Nrp1* and
166 *Tgfr1* siRNA, were detected by RT-qPCR (For Sham, $n=7$; Vehi+IRD5, $n=6$; *Nrp1*
167 siRNA+IRD5, $n=5$; *Nrp1* siRNA+*Tgfr1* siRNA+IRD5, $n=5$). (C) Representative
168 micrographs and corresponding statistical scores of PAS, Masson, and Sirius red staining
169 on day 14 after I-R in mice with myofibroblast-specific *Nrp1* knockout ($n = 7$ per group).
170 Ratio of kidney weight versus body weight of mice ($n = 7$ per group). Plasma BUN
171 concentrations and CR concentrations in sham, Vehi + IR, or Tmx + IR groups at 14 days
172 ($n = 7$ per group). (D) Co-expression of *Nrp1* with α -SMA with immunofluorescence staining.
173 (E) Representative micrographs and corresponding statistical scores of PAS, Masson, and
174 Sirius red staining on day 14 after I-R in mice with pericyte-specific *Nrp1* knockout ($n = 5$
175 per group). Ratio of kidney weight versus body weight of mice ($n = 5$ per group). Plasma
176 BUN concentrations and CR concentrations in sham, Vehi + IR, or Tmx + IR groups at 14
177 days ($n = 5$ per group). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ as determined by one-way
178 ANOVA. Scale bar, 20 μm . Data represent mean \pm SEM. Source data are provided as a
179 Source Data file.
180

181

Table S1. General characteristics of study participants (Related to Figure 1)

Variable	eGFR < 30 ml/min/1.73 m ² (n = 115)	eGFR ≥ 30 ml/min/1.73 m ² (n = 102)	<i>P</i>
Gender male	86/115(74.8%)	74/102(72.5%)	0.709 ^c
Age (years)	41.72±1.039	40.11±1.14	0.296 ^a
Hypertension positive	100/115(87.0%)	82/102(80.4%)	0.189 ^c
Diabetes positive	11/115(9.6%)	11/102(10.8%)	0.767 ^c
White blood cell,10 ⁹ /L	6.5±0.27	7.0±0.24	0.139 ^a
Neutrophil,10 ⁹ /L	4.66±0.25	4.56±0.22	0.765 ^a
Lymphocyte,10 ⁹ /L	1.37±0.16	1.78±0.07	0.031 ^a
Monocyte,10 ⁹ /L	0.55±0.04	0.57±0.22	0.561 ^a
Platelet,10 ⁹ /L	191.08±6.00	202.67±6.01	0.176 ^a
Na ⁺ ,mmol/L	139.78±0.29	140.38±0.19	0.099 ^a
K ⁺ ,mmol/L	7.27±2.76	4.32±0.06	0.321 ^a
Cl ⁻ ,mmol/L	105.2(101.5-109.1)	105.6(103.5-107.3)	0.453 ^b
Ca ²⁺ ,mmol/L	2.19±0.02	2.33±0.03	0.000 ^a
ALT,U/L	10(7-16)	11(7-16)	0.412 ^b
AST,U/L	14(11-18)	15(12-18)	0.134 ^b
Total protein,g/L	61.80±0.89	65.80±0.66	0.000 ^a
Albumin,g/L	36.04±0.65	39.08±0.53	0.000 ^a
Globulin,g/L	25.97±0.48	26.30±0.47	0.632 ^a
Cholesterol,mmol/L	4.57±0.14	4.69±0.14	0.539 ^a
Uric acid,μmol/L	390.19±11.37	381.81±10.13	0.583 ^a
Urinary red cell,μL	10.4(4.3-29.4)	8.1(3.9-31.1)	0.616 ^b
Urinary white cell,μL	6.6(2.7-11.5)	3.9(2.2-9.9)	0.146 ^b
Urinary cast,μL	0.1(0-0.4)	0.1(0-0.4)	0.811 ^b
NRP1 high,n%	73/115(63.5%)	46/102(45.1%)	0.007 ^c

182 The bold values indicate *P* < 0.05.

183 Data are presented as mean ± SEM or median (25–75th percentiles) or a percentage.

184 Tubular NRP1 high cell was defined as the number of NRP1 positive cells ≥50th
185 percentiles.186 ^at-test, ^bMann–Whitney U test, ^cPearson's chi-squared test.

187 All statistical analyses were two-sided.

188

189 **Table S2. Sequence for Nrp1 Used for Fluorescence in**
190 **Situ Hybridization (Related to methods section)**

Gene	Sequence(5'to3')
	GTAACCGGGAGATGTGAGGTACCC
	AGGATTCGAGTCTTGCTCCAGGTC
<i>Nrp1</i>	TGGATAGAACGCCTGAAGAGGAGC
	TGTGGCTCTCTCAGGGTAGATCCT
	CCAGAAGGTCATACAGTGGGCAGA

191

192

193 **Table S3. List and sequence for primers used for RT-qPCR(Related to methods**
 194 **section)**

Gene	Forward(5'to3')	Reverse(5'to3')
<i>Gapdh</i>	TGACCTCAACTACATGGTCTACA	CTTCCCATTCTCGGCCTTG
<i>Nrp1</i>	CAAGGAGTGGCACAGCATCT	GGAGCACCACATCCACAGAA
<i>Tgfbr1</i>	TCTGCATTGCACTTATGCTGA	AAAGGGCGATCTAGTGATGGA
<i>Havcr1</i>	ACATATCGTGGAATCACAACGAC	ACTGCTCTTCTGATAGGTGACA
<i>Lcn2</i>	GCAGGTGGTACGTTGTGGG	CTCTTGTAGCTCATAGATGGTGC
<i>Acta2</i>	CCCAGACATCAGGGAGTAATGG	TCTATCGGATACTTCAGCGTCA
<i>Pdgfrb</i>	AGGAGTGATACCAGCTTTAGTCC	CCGAGCAGGTCAGAACAAAGG
<i>Col1a1</i>	GCTCCTCTTAGGGGCCACT	CCACGTCTCACCATTGGGG
<i>Col1a2</i>	TCGTGCCTAGCAACATGCC	TTTGTGAGAATACTGAGCAGCAA
<i>Fn1</i>	GCTCAGCAAATCGTGCAGC	CTAGGTAGGTCCGTTCCCACT
<i>Nfkb1</i>	ATGGCAGACGATGATCCCTAC	CGGAATCGAAATCCCCTCTGTT
<i>Smad3</i>	CATTCCATTCCCAGAGAACAATAA	GCTGTGGTTCATCTGGTGGT
<i>Ndufa4</i>	TCCCAGCTTGATTCTCTCTT	GGGTTGTTCTTTCTGTCCCAG
<i>Sdhd</i>	TGGTCAGACCCGCTTATGTG	GGTCCAGTGGAGAGATGCAG
<i>Uqcrb</i>	GGCCGATCTGCTGTTTCAG	CATCTCGCATTAAACCCAGTT
<i>Cox7b</i>	TTGCCCTTAGCCAAAACGC	TCATGGAAACTAGGTGCCCTC
<i>Atp5o</i>	TCTCGACAGGTTCCGAGCTT	TTGACGGTGCGCTTGATGTAG
<i>Pdhb</i>	AAGAGGCGTTTTACCGCTC	GTCACCGTATTTCTTCCACAGG
<i>Acly</i>	ACCCTTTCACTGGGGATCACA	GACAGGGATCAGGATTTCTTG
<i>Oghd</i>	GTTTCTTCAAACGTGGGGTTCT	GCATGATTCCAGGGGTCTCAA
<i>Idh3a</i>	TGGGTGTCCAAGGTCTCTC	CTCCCCTGAATAGGTGCTTTG

195
 196

197 **References**

- 198 1. <https://singlecell.broadinstitute.org/>.
199 2. <https://www.spatialomics.org/SpatialDB>
200 3. <https://www.biorender.com>